Current projects

  1. Clinical trials (See Figure 1 below) 
    The clinical trials are run in the lung cancer section at the Dept of Oncology.
    1. DART - Durvalumab After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients
    2. NIPU - Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma
    3. COM-IT-2 - Combinatory ImmunoTherapy-2 (Com-IT-2) - a phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer
    4. ADIL - a phase 2 randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC
  2. Translational projects exploring mechanisms of treatment response and resistance (see Figure 1 below) 
    1. Gut microbiome profiling to identify alterations during chemoradiation and immunotherapy and identify biomarkers for therapy response
    2. Immune cell profiling of primary tumour tissue by multiplex immunohistochemistry and RNA-sequencing 
    3. Circulating immune markers to study immune response to therapy and identify predictive biomarkers (profiling of immune cells and cytokines)
    4. Evaluation of dual-time PET to elucidate tumour cell composition in response to therapy for patients with pleural mesothelioma in the NIPU-trial)
  3. Functional studies for combination treatments: immunotherapy, radiotherapy and targeted therapy
    1. Lung cancer functional testing (LUFT): I biobank of cancer cells and organoids for functional testing
    2. Cell lines
    3. PDX-models
Figure 1

 

Figure 2

 

 

 

 

 

 

 
Scroll to top